The Fiscal Year 2020 (FY20) Defense Appropriations Bill has not been signed into law. Although FY20 funds have not been appropriated for the Department of Defense Ovarian Cancer Research Program (OCRP), the OCRP is providing the information in this pre-announcement to allow investigators time to plan and develop ideas for submission to the anticipated FY20 funding opportunities. This pre-announcement should not be construed as an obligation by the Government.
The FY20 Defense Appropriations Act is anticipated to provide funding to the Department of Defense (DoD) Ovarian Cancer Research Program (OCRP) to support patient-centered research to prevent, detect, treat, and cure ovarian cancer to enhance the health and well-being of Service members, Veterans, retirees, their family members, and all women impacted by this disease. As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency J9, Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation. The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Development Command (USAMRDC).
FY20 OCRP Program Announcements and General Application Instructions for the following award mechanism is posted on the Grants.gov website.
Proteogenomics Research Award – Letter of Intent due July 16, 2020
Investigators at or above the postdoctoral level (or equivalent).
- Supports the use of proteomics and/or genomics to explore new concepts or theories in ovarian cancer.
- The proposed research question should be innovative and have the potential to make an impact on ovarian cancer.
- The analysis of clinical trial-derived specimens and/or large patient specimen cohorts is encouraged.
- The use of the unique proteomics resource at the Women’s Health Integrated Research Center Clinical Proteomics Platform through the Department of Defense intramural Gynecologic Cancer Center of Excellence is encouraged.
- Preliminary data are not required but allowed.
- Clinical trials are not allowed.
- Submission of a Letter of Intent (LOI) is required prior to full application submission.
· Maximum funding of $250,000 for direct costs (plus indirect costs)
· Maximum period of performance is 2 years.
A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline. All applications must conform to the final Program Announcements and General Application Instructions available for electronic downloading from the Grants.gov website. The application package containing the required forms for each award mechanism will also be found on Grants.gov. A listing of all CDMRP and other USAMRDC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420.
For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org. For more information about the OCRP or other CDMRP-administered programs, please visit the CDMRP website (https://cdmrp.army.mil).
Point of Contact:CDMRP Help Desk